Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Key claim: The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 (S4472) would reauthorize federal programs that expand access to investigational and critical therapies for patients with amyotrophic lateral sclerosis.
Abstract
(S4472 · 119th Congress) Latest action (2026-07-16): Placed on Senate Legislative Calendar under General Orders. Calendar No. 461.
Why this matters
Reauthorizing the ALS critical therapies framework preserves an expedited route for ALS patients to obtain investigational treatments outside of standard approval timelines, which is significant given the disease’s rapid progression and limited treatment options. For patients and providers, continuity of these programs affects whether early-access mechanisms remain available; for insurers and FDA regulators, it maintains a defined federal pathway distinct from standard clinical trial enrollment. The bill is at introduced stage, so operational impact depends on advancement through Congress.